NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
14/08/2026
Voltar para busca
Dado oficial do USPTO
SYNPLOGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
14/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
22/08/2019
Data de registro
04/08/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/08/2026
Última transação
14/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Hyogo, JP
Examinador
VO, JULIE
Localização atual
Historical data usage
Titulares e representantes
Titulares
Synplogen Co., Ltd.
Representantes
Kumiko Ide Wenderoth, Lind & Ponack, L.L.P.
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology consulting services relating to DNA synthesis technology; research and development in the fields of bacteriologycytologyantibody technologychemistryimmunologygene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and developmentquality control for otherstechnical advisory services relating thereto in the fields of proteinantibodymicroorganismscells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; * providing * technical advisory services and information technology consulting services relating to genome synthesis technology; research and developmentquality control for otherstechnical advisory services relating thereto in the fields of proteinantibodymicroorganismscellsall with genome synthesis technology; research and development in the fields of bacteriologycytologyantibody technologychemistryimmunologygene expression systemsall with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testinginspection and research of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; development of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; * providing * technical advisory services relating to development of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; information technology services relating to development of pharmaceuticalscosmetics or foodstuffsall with genome synthesis technology; testinginspection and research relating to medical treatment or medical technology with genome synthesis technology; * providing * information technology consulting services for testinginspection or research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testinginspection or research on agriculturelivestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others for scientific research purposes ; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; DNA sequence design services for scientific research purposes; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
71AG
REGISTERED-SEC.71 ACCEPTED
14/08/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2026
ES71
TEAS SECTION 71 RECEIVED
21/04/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/08/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
17/02/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
24/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
30/07/2022
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
25/04/2022
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
24/04/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/02/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/12/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/11/2020
FIMP
FINAL DISPOSITION PROCESSED
25/11/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/11/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
04/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/05/2020
PUBO
PUBLISHED FOR OPPOSITION
19/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/03/2020
ALIE
ASSIGNED TO LIE
19/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
31/01/2020
GNRT
NON-FINAL ACTION E-MAILED
31/01/2020
CNRT
NON-FINAL ACTION WRITTEN
31/01/2020
RFNT
REFUSAL PROCESSED BY IB
17/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/01/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/01/2020
RFRR
REFUSAL PROCESSED BY MPU
02/01/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/12/2019
CNRT
NON-FINAL ACTION WRITTEN
03/12/2019
MAFR
APPLICATION FILING RECEIPT MAILED
26/11/2019
DOCK
ASSIGNED TO EXAMINER
22/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/11/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNPLOGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.